ADIAL PHARMACEUTICALS, INC. — Director's Dealing 2018

Aug 2, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK: 0001513525
Period of Report: 2018-07-31

Reporting Person: Gilliland Robertson H. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-31	Common Stock	C	29931	—	Acquired	95424	Indirect
2018-07-31	Common Stock	P	14000	—	Acquired	109424	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-31	Convertible Note	$0.44	C	29931	Disposed		Common Stock (29931)	Indirect
2018-07-31	Warrant to purchase common stock	$6.25	C	29931	Acquired	2023-07-31	Common Stock (29931)	Indirect
2018-07-31	Warrant to purchase common stock	$6.25	P	14000	Acquired	2023-07-31	Common Stock (43931)	Indirect

Footnotes

F1: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 at a conversion price of $0.44 per share upon consummation of the initial public offering of the issuer on July 31, 2018.

F2: Mr. Gilliland is the principal of Keller Enterprises, LLC ("Keller").

F3: On July 31, 2018, Keller purchased 14,000 units (the "Units") in the initial public offering of the issuer at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the IPO.